Patent · US Expired

Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin

US6239124A · kind A · utility

42Cited by

2References

20Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Gerhard Zenke · Rheinfelden (Baden), DE
Hendrik Schuurman · Basel, CH
Barbara Haeberlin · Riehen, CH
Armin Meinzer · Glückstadt, DE

Key dates

Filing date	Jan 28, 1999
Grant date	May 29, 2001
Priority date	—
Expiry date	Jan 28, 2019

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.